Literature DB >> 21648285

Pediatric 25-hydroxyvitamin D concentrations in neurofibromatosis type 1.

David A Stevenson1, David H Viskochil, John C Carey, Xiaoming Sheng, Mary Murray, Laurie Moyer-Mileur, Judd Shelton, William L Roberts, Ashley M Bunker, Heather Hanson, Stephanie Bauer, Jacques L D'Astous.   

Abstract

OBJECTIVE: Low 25-hydroxyvitamin D (25OHD) concentrations have been associated with tumors and osteopenia or fractures in adults with neurofibromatosis type 1 (NF1). We report 25OHD concentrations in 109 children with NF1 and 218 controls matched for age, sex, geographic location, and time of year.
METHODS: Children with NF1 were recruited (n=109; 2-17 years), and clinical data and dual-energy X-ray absorptiometry measurements were obtained. 25OHD concentrations were measured in subjects and controls.
RESULTS: More NF1 individuals (50%) were in the 25OHD insufficient or deficient range (<30 ng/mL) (1 ng/mL = 2.496 nmol/L) compared to controls (36%) (p = 0.0129). 25OHD concentrations were higher in individuals with neurofibromas after controlling for age (p = 0.0393), and were negatively associated with whole-body subtotal bone mineral density (BMD) z-scores (p = 0.0385).
CONCLUSIONS: More children with NF1 had 25OHD concentrations <30 ng/mL, potentially because of increased pigmentation and/or decreased sunlight exposure. In contrast to adults, decreased 25OHD concentrations were not associated with neurofibromas, and there was no positive association between 25OHD and BMD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21648285      PMCID: PMC3246508          DOI: 10.1515/jpem.2011.092

Source DB:  PubMed          Journal:  J Pediatr Endocrinol Metab        ISSN: 0334-018X            Impact factor:   1.634


  36 in total

Review 1.  Neurofibromas in children with neurofibromatosis 1.

Authors:  Tena Rosser; Roger J Packer
Journal:  J Child Neurol       Date:  2002-08       Impact factor: 1.987

Review 2.  Genetics of neurofibromatosis 1 and the NF1 gene.

Authors:  David Viskochil
Journal:  J Child Neurol       Date:  2002-08       Impact factor: 1.987

Review 3.  NF1 gene and neurofibromatosis 1.

Authors:  S A Rasmussen; J M Friedman
Journal:  Am J Epidemiol       Date:  2000-01-01       Impact factor: 4.897

4.  Vitamin D3 analogues improve café au lait spots in patients with von Recklinghausen's disease: experimental and clinical studies.

Authors:  J Nakayama; H Kiryu; K Urabe; S Matsuo; S Shibata; T Koga; M Furue
Journal:  Eur J Dermatol       Date:  1999 Apr-May       Impact factor: 3.328

5.  Congenital pseudarthrosis of the tibia.

Authors:  H A Sofield
Journal:  Clin Orthop Relat Res       Date:  1971-05       Impact factor: 4.176

6.  SPRED 1 mutations in a neurofibromatosis clinic.

Authors:  Talia M Muram-Zborovski; David A Stevenson; David H Viskochil; David C Dries; Andrew R Wilson
Journal:  J Child Neurol       Date:  2010-02-22       Impact factor: 1.987

7.  Type 1 neurofibromatosis: a descriptive analysis of the disorder in 1,728 patients.

Authors:  J M Friedman; P H Birch
Journal:  Am J Med Genet       Date:  1997-05-16

8.  Congenital pseudarthrosis of the tibia.

Authors:  R T Morrissy; E J Riseborough; J E Hall
Journal:  J Bone Joint Surg Br       Date:  1981

9.  Congenital pseudarthrosis of the tibia. Long-term followup of 29 cases treated by microvascular bone transfer.

Authors:  A Gilbert; R Brockman
Journal:  Clin Orthop Relat Res       Date:  1995-05       Impact factor: 4.176

10.  Orthopaedic manifestations of neurofibromatosis in children: an update.

Authors:  Michael G Vitale; Abhijit Guha; David L Skaggs
Journal:  Clin Orthop Relat Res       Date:  2002-08       Impact factor: 4.176

View more
  5 in total

Review 1.  Diagnosis and treatment of osteopenic fractures in children.

Authors:  Charles T Mehlman; Marcia A Shepherd; Carie S Norris; Jessica B McCourt
Journal:  Curr Osteoporos Rep       Date:  2012-12       Impact factor: 5.096

2.  Vitamin D Status and VDR Genotype in NF1 Patients: A Case-Control Study from Southern Brazil.

Authors:  Larissa Souza Mario Bueno; Clévia Rosset; Ernestina Aguiar; Fernando de Souza Pereira; Patrícia Izetti Ribeiro; Rosana Scalco; Camila Matzenbacher Bittar; Cristina Brinckmann Oliveira Netto; Guilherme Gischkow Rucatti; José Artur Chies; Suzi Alves Camey; Patricia Ashton-Prolla
Journal:  Int J Endocrinol       Date:  2015-06-16       Impact factor: 3.257

Review 3.  The skeletal muscle phenotype of children with Neurofibromatosis Type 1 - A clinical perspective.

Authors:  Amish Chinoy; Grace R Vassallo; Emma Burkitt Wright; Judith Eelloo; Siobhan West; Eileen Hupton; Paula Galloway; Amy Pilkington; Raja Padidela; M Zulf Mughal
Journal:  J Musculoskelet Neuronal Interact       Date:  2022-03-01       Impact factor: 1.864

4.  Bone metabolism in patients with type 1 neurofibromatosis: key role of sun exposure and physical activity.

Authors:  Ursula Pia Ferrara; Cristina Tortora; Carmen Rosano; Antonia Assunto; Alessandro Rossi; Stefano Pagano; Mariateresa Falco; Chiara Simeoli; Rosario Ferrigno; Alessandra D'Amico; Dario Di Salvio; Giuliana Cangemi; Rosario Pivonello; Pietro Strisciuglio; Daniela Melis
Journal:  Sci Rep       Date:  2022-03-14       Impact factor: 4.379

5.  Determination of Vitamin D Levels in Patients With Neurofibromatosis Type 1 in the Pediatric Age Group.

Authors:  Alessandra Santos; Mauro Geller; Spyros Mezitis; Allan E Rubenstein; Lisa Oliveira; Daniel Jm Medeiros Lima; Mendel Suchmacher Neto; Rafael Nigri; Karin Gonçalves Soares Cunha; Sanyu Takirambudde; Marcia Gonçalves Ribeiro
Journal:  Clin Pathol       Date:  2020-10-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.